Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
50g |
|
||
Other Sizes |
|
Purity: ≥98%
Estradiol (Oestradiol; Estrace; Dihydrofolliculin; β-Estradiol; 17β-estradiol, β-Estradiol; E2; 17β-Oestradiol), the 17-beta-isomer of estradiol, is an endogenous/naturally occuring estrogen steroid hormone and a primary female sex hormone that is involved in the regulation of the estrous and menstrual female reproductive cycles.
Targets |
Endogenous Metabolite
|
---|---|
ln Vitro |
Estradiol (10 nM, 7 d) stimulates neuronal development and enhances axonal branching in human endometrial stem cells (hEnSCs) [1]. Estradiol (17β-estradiol, 10 nM, 7 days) boosts the expression of neuron-like cell markers (Tuj-1, nestin and NF-H) in neuronal-like cells generated from hEnSCs [1].
|
ln Vivo |
Estradiol (1 nM, hippocampus slices from FBN-ARO-KO mice) restores LTP amplitude [1]. Estradiol (0.0167 mg, subcutaneously implanted) corrects molecular and functional abnormalities in FBN-ARO-KO mice [1].
|
Cell Assay |
Cell Differentiation Assay[1]
Cell Types: Isolated human endometrial stem cells (hEnSCs) from human endometrial tissue Tested Concentrations: 10 nM Incubation Duration: 7 days Experimental Results: Increased the number of neurite processes including neural differentiation and neurite branching. Immunofluorescence[1] Cell Types: Isolated human endometrial stem cells (hEnSCs) from human endometrial tissue Tested Concentrations: 10 nM Incubation Duration: 7 days Experimental Results: Increased the percentage of neural marker (Tuj-1, nestin and NF-H)-positive cells of 62.2±1.3%, 71.5±4% and 51.2±1.5% respectively. |
Animal Protocol |
Animal/Disease Models: FBN-ARO-KO Mice[2]
Doses: 1 nM Route of Administration: Treated for the hippocampal slices Experimental Results: Rescued long-term potentiation (LTP) amplitude of both male and female mice. Animal/Disease Models: FBN-ARO-KO Mice [2] Doses: 0.0167 mg Route of Administration: Alzet minipumps with Estradiol (implanted sc), examined 7 days after minipump implantation. Experimental Results: Restored hippocampal and cortical E2 levels to 93%, phosphorylation of AKT, ERK and CREB in the hippocampus and cortex to 90-95%, BDNF level to 80-90%, restored both synaptophysin and PSD95 in the forebrain. Rescued the spatial learning and memory defects. |
References |
[1]. Elham Hasanzadeh. Defining the role of 17β-estradiol in human endometrial stem cells differentiation into neuron-like cells. Cell Biol Int. 2021 Jan;45(1):140-153.
[2]. Yujiao Lu, et al. Neuron-Derived Estrogen Regulates Synaptic Plasticity and Memory. J Neurosci. 2019 Apr 10;39(15):2792-2809. |
Molecular Formula |
C18H24O2
|
|
---|---|---|
Molecular Weight |
272.38
|
|
Exact Mass |
272.17763
|
|
Elemental Analysis |
C, 79.37; H, 8.88; O, 11.75
|
|
CAS # |
50-28-2
|
|
Related CAS # |
Alpha-Estradiol;57-91-0;Estradiol (Standard);50-28-2;Estradiol-d3;79037-37-9;Estradiol-d4;66789-03-5;Estradiol-d5;221093-45-4;Estradiol-13C2;82938-05-4;Estradiol (cypionate);313-06-4;Estradiol benzoate;50-50-0;Estradiol enanthate;4956-37-0;Estradiol hemihydrate;35380-71-3;Estradiol-d2;53866-33-4;Estradiol-13C6;Estradiol-d2-1;3188-46-3;rel-Estradiol-13C6
|
|
Appearance |
White to off-white solid powder
|
|
LogP |
4
|
|
tPSA |
40.5Ų
|
|
SMILES |
O([H])[C@@]1([H])C([H])([H])C([H])([H])[C@@]2([H])[C@]3([H])C([H])([H])C([H])([H])C4C([H])=C(C([H])=C([H])C=4[C@@]3([H])C([H])([H])C([H])([H])[C@@]21C([H])([H])[H])O[H]
|
|
InChi Key |
VOXZDWNPVJITMN-ZBRFXRBCSA-N
|
|
InChi Code |
InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1
|
|
Chemical Name |
(8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (9.18 mM) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.18 mM) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.08 mg/mL (7.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 5: ≥ 2.08 mg/mL (7.64 mM)(saturation unknown) in ≥ 2.5 mg/mL (5.35 mM) (add these co-solvents sequentially from left to right, and one by one),clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 6: 12.5 mg/mL (45.89 mM) in Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.6713 mL | 18.3567 mL | 36.7134 mL | |
5 mM | 0.7343 mL | 3.6713 mL | 7.3427 mL | |
10 mM | 0.3671 mL | 1.8357 mL | 3.6713 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.